Pleasanton, California, USA, and Boston, Massachusetts, USA, November 13, 2026
Dana-Farber Cancer Institute has integrated the n6 icon96™ system, developed by n6 Tec, Inc., into its Molecular Biology Core Facilities’ low-input cell-free DNA (cfDNA) sequencing service, marking an important advancement in liquid biopsy research and next-generation sequencing technology. The integration is designed to improve the consistency of DNA library preparation, particularly when working with limited quantities of biological samples obtained from patients. The upgraded workflow combines iconPCR™ technology and AutoNorm adaptive amplification with dual unique molecular identifier (UMI) library preparation, hybrid capture and duplex sequencing. According to the announcement, the integrated workflow reduced library-yield variability from 54% to 8% in 10 ng cfDNA samples and supported reliable detection of genetic variants at frequencies as low as 0.5% using only 1 ng of cfDNA in reference-standard testing. These improvements are particularly relevant to liquid biopsy research, where detecting rare tumour-derived genetic alterations requires highly sensitive sequencing methods and careful sample preparation. The collaboration demonstrates how advanced laboratory automation and adaptive amplification technologies can help researchers improve sequencing consistency while preserving valuable genetic material.
iconPCR Technology Improves Low-Input DNA Sequencing
One of the major challenges in cfDNA sequencing is the limited quantity of genetic material available for analysis. Cell-free DNA consists of short DNA fragments circulating outside cells in biological fluids, including blood plasma. In cancer research, a small proportion of this DNA may originate from tumour cells, making it possible to investigate genetic alterations through liquid biopsy approaches. However, tumour-derived variants can occur at very low allele frequencies, sometimes below 1%, requiring highly sensitive molecular analysis. Conventional polymerase chain reaction (PCR) workflows often apply a fixed number of amplification cycles across all samples. This can create inconsistencies because samples containing different starting quantities of DNA may respond differently to the same amplification conditions. Low-input samples may produce insufficient DNA for downstream sequencing, while samples with higher starting quantities may become over-amplified, increasing duplicate sequences and affecting library quality. The n6 icon96 system addresses this challenge through independent thermal control and real-time amplification monitoring across 96 wells. Its AutoNorm software allows each sample to stop amplification when it reaches a predefined endpoint. This sample-specific approach helps laboratories process samples with different DNA concentrations in the same run without requiring extensive manual quantification, dilution or normalisation.
Sequencing Workflow Demonstrates Improved Analytical Performance
Dana-Farber’s Molecular Biology Core Facilities reported several improvements following the integration of icon96 into its cfDNA sequencing workflow. In 10 ng samples, the coefficient of variation in library yield decreased from 54% with fixed-cycle amplification to 8% using AutoNorm. At 1 ng input, the reported coefficient of variation was 30%. Importantly, samples containing 1 ng and 10 ng of cfDNA could be processed together in the same run. The integrated workflow also achieved on-target sequencing rates exceeding 90%, with consistent performance across four evaluated sample sets involving 1 ng and 10 ng inputs. On-target capture is an important sequencing quality measure because it indicates the proportion of sequencing reads corresponding to the intended genomic regions. In reference-standard experiments using Twist reference materials, the workflow reliably detected all spiked variants down to 0.5% allele frequency at both 1 ng and 10 ng input levels. Mean target coverage exceeded 200× for the 1 ng samples. The technology was also evaluated using patient-derived cfDNA samples ranging from approximately 2 ng to 25 ng. These samples were normalised within a single run, and all generated sufficient library material to proceed to hybrid capture. Together, these findings demonstrate the potential of adaptive amplification to improve consistency in challenging low-input sequencing applications.
Advancing Liquid Biopsy and Cancer Research Capabilities
The upgraded Dana-Farber cfDNA service combines the IDT xGen cfDNA and FFPE DNA Library Preparation Kit, dual-UMI duplex sequencing, n6 icon96 amplification, hybrid capture and sequencing using the Illumina NovaSeq X Plus platform. The combination of these technologies is designed to support accurate molecular analysis while helping researchers preserve valuable genetic information from limited biological samples. Dual-UMI methods are particularly useful in liquid biopsy research because they help distinguish genuine genetic variants from errors introduced during DNA amplification and sequencing. The integration is expected to benefit research programmes investigating tumour-associated genetic alterations, cancer biomarkers and molecular changes associated with disease progression. For pharmaceutical and biotechnology researchers, improved low-input sequencing workflows can also support biomarker discovery, translational research and the investigation of potential therapeutic targets. The integration of n6 iconPCR into Dana-Farber’s sequencing service represents an important step towards more consistent and efficient cfDNA research workflows. However, n6 states that its products are intended for research use only and are not intended for diagnostic procedures. The reported findings therefore demonstrate research workflow performance rather than validation of a clinical diagnostic test.
Source: Dana-Farber Cancer Institute, n6 Tec press release



